1. Search Result
Search Result
Results for "

breast cancer and endometriosis

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-178419

    GnRH Receptor Cancer
    GnRH-R antagonist-3 (Compound 37) is a Gonadotropin releasing hormone receptor (GnRH-R) antagonist with IC50s of 94 and 275 nM for rat and human GnRH-R, respectively. GnRH-R antagonist-3 can be used for hormone dependent diseases such as endometriosis, breast and prostate cancer research .
    GnRH-R antagonist-3
  • HY-W267205

    17β-HSD Endocrinology Cancer
    3-Acetyl-7-Hydroxycoumarin (Compound 2) is a high selective 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. 3-Acetyl-7-Hydroxycoumarin shows a significant improvement of the inhibitory potency, with 57% inhibition of 17β-HSD1 at 6 μM. 3-Acetyl-7-Hydroxycoumarin is promising for research of hormone-dependent diseases, such as breast cancer and endometriosis .
    3-Acetyl-7-Hydroxycoumarin
  • HY-178418

    GnRH Receptor Cancer
    GnRH-R antagonist-2 (Compound 44c) is a Gonadotropin releasing hormone receptor (GnRH-R) antagonist with IC50s of 43 and 88 nM for rat and human GnRH-R, respectively. GnRH-R antagonist-2 can be used for hormone dependent diseases such as endometriosis, breast and prostate cancer research .
    GnRH-R antagonist-2
  • HY-119080

    Progesterone Receptor Endocrinology Cancer
    CP8754 is an orally active, selective human progesterone receptor (hPR) antagonist that blocks progesterone-mediated signaling pathways. CP8754 competitively inhibits the binding of [ 3H]-progesterone to hPR. And in vitro, CP8754 inhibits progesterone-dependent exogenous luciferase and endogenous alkaline phosphatase expression; while in vivo, CP8754 inhibits rabbit endometrial transformation. CP8754 does not significantly bind to human glucocorticoid receptors (hGR), estrogen receptors (hER), or rat androgen receptors (rAR). CP8754 can be used in the study of progesterone-related diseases such as breast cancer, endometriosis, uterine fibroids, and meningioma, as well as hormone-dependent tumors .
    CP8754
  • HY-179528

    Nuclear Hormone Receptor 4A/NR4A Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Transferrin Receptor Apoptosis Bcl-2 Family Caspase Endocrinology Cancer
    DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM and 12.0 μM for NR4A1 and NR4A2, respectively. DIM-3,5-Cl2 acts as an inverse agonist to downregulate pro-oncogenic and proendometriotic gene products, and as an agonist to enhance NR4A1/2/Sp1/Sp4-mediated CD71 transactivation. DIM-3,5-Cl2 induces ferroptosis via ROS formation, lipoperoxidation, MDA production, and reduced GPX4, SLC7A11 expression. DIM-3,5-Cl2 induces apoptosis via PARP and caspase-3 cleavage, reduced BCL-2 expression, and inhibits cancer cell viability. DIM-3,5-Cl2 can be used for the research of triple negative breast cancer, endometriosis, and colorectal cancer .
    DIM-3,5-Cl2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: